High expression of HDAC6 was found to promote protumor phenotypes in TAMs, and HDAC6 inhibition improved the response of breast cancer to ICB in part by stimulating an antitumor immune response [238, 239]. This evidence concerns the gene HDAC6 and breast carcinoma.